Conditioned Medium of Lipopolysaccharide-Treated Embryonic Stem Cell-Derived Mesenchymal Stem Cells Modulates in Vitro Secretion of Inflammatory Cytokines
Abstract
Background: The immunomodulatory properties of MSCs secretome have been considered by many investigators, and several preconditioning strategies such as pharmaceutical preconditioning have shown to strengthen the immunomodulatory outcomes of MSCs. Objectives: Current research aimed to scrutinize the release of some main inflammatory related cytokines in peripheral blood mononuclear cells (PBMCs) induced by lipopolysaccharide (LPS) following the treatment with secretome of LPS-preconditioned human embryonic stem cell-derived mesenchymal stem cells (hESC-MSCs).
Material and methods: First, hESC-MSCs were cultivated and characterized, then they were preconditioned with 1µg/mL of LPS. The conditioned medium was collected and concentrated 15-folds. In the next step, PBMCs were separated from human peripheral blood and processed by concentrated LPS-preconditioned hESC-MSC secretome. Subsequently, PBMCs were induced by 1µg/mL of LPS. Finally, the secreted amounts of TNFα, IL-1β, and IL-10 were investigated via ELISA assay.
Results: LPS-preconditioned hESC-MSC secretome considerably enhanced the secretion of IL-10 and IL-1β in PBMCs (p>.0.0001). The change of secreted level in TNFα was not significant.
Conclusion: The results implied that LPS could support the immunomodulatory outcomes of hESC-MSC secretome.
Background: The immunomodulatory properties of MSCs secretome have been considered by many investigators, and several preconditioning strategies such as pharmaceutical preconditioning have shown to strengthen the immunomodulatory outcomes of MSCs. Objectives: Current research aimed to scrutinize the release of some main inflammatory related cytokines in peripheral blood mononuclear cells (PBMCs) induced by lipopolysaccharide (LPS) following the treatment with secretome of LPS-preconditioned human embryonic stem cell-derived mesenchymal stem cells (hESC-MSCs).
Material and methods: First, hESC-MSCs were cultivated and characterized, then they were preconditioned with 1µg/mL of LPS. The conditioned medium was collected and concentrated 15-folds. In the next step, PBMCs were separated from human peripheral blood and processed by concentrated LPS-preconditioned hESC-MSC secretome. Subsequently, PBMCs were induced by 1µg/mL of LPS. Finally, the secreted amounts of TNFα, IL-1β, and IL-10 were investigated via ELISA assay.
Results: LPS-preconditioned hESC-MSC secretome considerably enhanced the secretion of IL-10 and IL-1β in PBMCs (p>.0.0001). The change of secreted level in TNFα was not significant.
Conclusion: The results implied that LPS could support the immunomodulatory outcomes of hESC-MSC secretome.
Material and methods: First, hESC-MSCs were cultivated and characterized, then they were preconditioned with 1µg/mL of LPS. The conditioned medium was collected and concentrated 15-folds. In the next step, PBMCs were separated from human peripheral blood and processed by concentrated LPS-preconditioned hESC-MSC secretome. Subsequently, PBMCs were induced by 1µg/mL of LPS. Finally, the secreted amounts of TNFα, IL-1β, and IL-10 were investigated via ELISA assay.
Results: LPS-preconditioned hESC-MSC secretome considerably enhanced the secretion of IL-10 and IL-1β in PBMCs (p>.0.0001). The change of secreted level in TNFα was not significant.
Conclusion: The results implied that LPS could support the immunomodulatory outcomes of hESC-MSC secretome.
Background: The immunomodulatory properties of MSCs secretome have been considered by many investigators, and several preconditioning strategies such as pharmaceutical preconditioning have shown to strengthen the immunomodulatory outcomes of MSCs. Objectives: Current research aimed to scrutinize the release of some main inflammatory related cytokines in peripheral blood mononuclear cells (PBMCs) induced by lipopolysaccharide (LPS) following the treatment with secretome of LPS-preconditioned human embryonic stem cell-derived mesenchymal stem cells (hESC-MSCs).
Material and methods: First, hESC-MSCs were cultivated and characterized, then they were preconditioned with 1µg/mL of LPS. The conditioned medium was collected and concentrated 15-folds. In the next step, PBMCs were separated from human peripheral blood and processed by concentrated LPS-preconditioned hESC-MSC secretome. Subsequently, PBMCs were induced by 1µg/mL of LPS. Finally, the secreted amounts of TNFα, IL-1β, and IL-10 were investigated via ELISA assay.
Results: LPS-preconditioned hESC-MSC secretome considerably enhanced the secretion of IL-10 and IL-1β in PBMCs (p>.0.0001). The change of secreted level in TNFα was not significant.
Conclusion: The results implied that LPS could support the immunomodulatory outcomes of hESC-MSC secretome.
Full Text:
152-158;PDFRefbacks
- There are currently no refbacks.